drugset
drugset / Trial / NCT05277675

Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)

NCT05277675 ↗

Unknown 160 enrolled Southwest Hospital, China
RandomizedParallel-groupSingle-blindTreatment

Summary

1. To compare systemic neoadjuvant therapy (combination of immune checkpoint inhibitors and anti-angiogenic drugs (short for "targeted-immune therapy") combined with radiofrequency ablation (RFA) and RFA alone in the treatment of recurrent hepatocellular carcinoma(HCC) in 1-year recurrence-free survival (RFS) and overall survival (OS) 2. To evaluate the clinical value of systemic neoadjuvant therapy (i.e. immune checkpoint inhibitors and targeted therapy) combined with RFA in the treatment of recurrent HCC, as well as the safety and efficacy of this strategy.

Timeline

Start
2021-11-01
Primary completion
2022-11-01
Completion
2023-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — —
Subject Lenvatinib Small molecule — —
Subject Sintilimab Monoclonal antibody — —
Subject Tislelizumab Monoclonal antibody — —

Indications

hepatocellular carcinoma